BioSpace News Archive

PDS Biotechnology Corporation announced that Frank Bedu-Addo, PhD, President and Chief Executive Officer of PDS Biotech, will participate in a fireside chat at the B. Riley Securities 4th Annual Oncology Conference taking place virtually on Thursday, January 18, 2024, at 10:00 AM EST.

Integer Holdings Corporation, a leading medical device outsource manufacturer, will join medtech leaders and innovators around the world in exhibiting at the North American Neuromodulation Society Annual Meeting at Caesars Palace in Las Vegas from Jan. 18 – 21, 2024.

Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that it has been granted orphan drug designation (ODD) from the U.S. Food and Drug Administration (FDA) for SGT-003, the company’s next-generation Duchenne muscular dystrophy (Duchenne) gene therapy candidate.

Orbis International announces an important in-kind and financial donation from NIDEK to support Orbis’s artificial intelligence -based screening services in Vietnam.

BioIVT, a global research partner and biospecimen solutions provider for drug and diagnostic development, will exhibit its latest Cell and Gene Therapy innovations at Advanced Therapies Week, taking place at the Miami Beach Convention Center from January 16-19.

Charles River Laboratories International, Inc. announced the launch of its off-the-shelf Rep/Cap plasmid offering, designed to streamline adeno-associated virus -based gene therapy programs.

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX) today announced that results showing retinal structure improvements with RG6501(OpRegen) from a Phase 1/2a clinical study (ClinicalTrials.gov Identifier: NCT02286089) in geographic atrophy (GA) secondary to advanced age-related macular degeneration (AMD), will be presented at the 2024 Angiogenesis, Exudation, and Degeneration Meeting.

Ferring Pharmaceuticals announced that ADSTILADRIN® is now fully available across the U.S. for healthcare providers to prescribe for their adult patients with high-risk Bacillus Calmette-Guérin -unresponsive non-muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors.

Cardiac Dimensions® announced that renowned interventional cardiologist Satya Shreenivas, MD, MBA has joined the company as Chief Medical Officer.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) (“Halozyme”) today announced that Takeda received U.S. Food and Drug Administration (FDA) approval for HYQVIA® [Immune Globulin Infusion 10% (Human)] co-formulated with Halozyme’s ENHANZE® drug delivery technology for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) as maintenance therapy to prevent the relapse of neuromuscular disability and impairment in adults.